“…Through the recognition of these receptors by targeting ligands on MSNs, more smart targeting strategies have been achieved. The targeting ligands now used for MSN-based HCC theranostics include lactobionic acid (Zhang et al, 2012), folic acid (Chen et al, 2019), arginine-glycine-aspartate (RGD) (Chen et al, 2012), transferring (Hao et al, 2017), hyaluronic acid (Lee et al, 2018), low-density lipoprotein (LDL) (Ao et al, 2018), and others ( Table 1).…”